US Edition#BeOne Medicines Achieves EMA PRIME Designation for BGB-16673 and Prepares for EHA 2025 with Cutting-Edge Clinica...
Summary by csimarket.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
#BeOne Medicines Achieves EMA PRIME Designation for BGB-16673 and Prepares for EHA 2025 with Cutting-Edge Clinica...
BeOne Medicines: Pioneering Oncology Innovations with PRIME Designation and Groundbreaking Research at EHA 2025 SAN CARLOS, Calif. In a significant development for the oncology sector, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235) has received the coveted PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA) for its experimental Bruton Tyrosine Kinase (BTK) degrader, BGB-16673. This innovative therapy is …
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
